Frontiers in neuroscience · 2025
Late-onset severe neutropenia in patients with relapsing remitting multiple sclerosis treated with ocrelizumab: case report and literature review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tauro Catherine, Awada Zeinab, Malhotra Radhika, Harel Asaff
Аннотация
OBJECTIVE: To describe two cases of recurrent, delayed-onset severe neutropenia several months following ocrelizumab therapy in patients with relapsing-remitting multiple sclerosis (RRMS).
BACKGROUND: A rare adverse effect of ocrelizumab is neutropenia, with late-onset neutropenia (LON) occurring more rarely. Literature guiding management of transient recurrent neutropenia in the setting of anti-CD20 therapy is lacking.
METHODS: Case 1: 38-year-old female emergency physician with RRMS developed severe transient spontaneously resolving asymptomatic neutropenia 3 months after ocrelizumab infusion. Two years later, she developed severe symptomatic LON and required antibiotics and granulocyte colony-stimulating factor (GCSF). Ocrelizumab was held, patient switched to ozanimod, but neutropenia recurred. Due to concerns of MS progression, ocrelizumab was restarted after the patient transitioned to a telehealth setting, with no recurrence of neutropenia at one-year follow-up. Case 2: 35-year-old male emergency physician with RRMS developed severe transient spontaneously resolving asymptomatic neutropenia 3 months after ocrelizumab infusion. Ocrelizumab was resumed after absolute neutrophil count recovery. Two years later, he developed moderate symptomatic LON during a suspected viral illness. Ocrevus was discontinued at this point. A subsequent episode occurred 3 months later during confirmed rhinovirus infection, again resolving promptly.
CONCLUSION: These cases highlight the unpredictable nature of recurrent LON with ocrelizumab and suggest the possibility of immune-mediated marrow suppression, potentially unmasked or worsened by infections, rather than direct drug toxicity, highlighting the need for clearer management guidelines.
BACKGROUND: A rare adverse effect of ocrelizumab is neutropenia, with late-onset neutropenia (LON) occurring more rarely. Literature guiding management of transient recurrent neutropenia in the setting of anti-CD20 therapy is lacking.
METHODS: Case 1: 38-year-old female emergency physician with RRMS developed severe transient spontaneously resolving asymptomatic neutropenia 3 months after ocrelizumab infusion. Two years later, she developed severe symptomatic LON and required antibiotics and granulocyte colony-stimulating factor (GCSF). Ocrelizumab was held, patient switched to ozanimod, but neutropenia recurred. Due to concerns of MS progression, ocrelizumab was restarted after the patient transitioned to a telehealth setting, with no recurrence of neutropenia at one-year follow-up. Case 2: 35-year-old male emergency physician with RRMS developed severe transient spontaneously resolving asymptomatic neutropenia 3 months after ocrelizumab infusion. Ocrelizumab was resumed after absolute neutrophil count recovery. Two years later, he developed moderate symptomatic LON during a suspected viral illness. Ocrevus was discontinued at this point. A subsequent episode occurred 3 months later during confirmed rhinovirus infection, again resolving promptly.
CONCLUSION: These cases highlight the unpredictable nature of recurrent LON with ocrelizumab and suggest the possibility of immune-mediated marrow suppression, potentially unmasked or worsened by infections, rather than direct drug toxicity, highlighting the need for clearer management guidelines.